Regeneron Pharma Q2 Results Top Estimates - Update

RTTNews | hace 389
Regeneron Pharma Q2 Results Top Estimates - Update

(RTTNews) - Biotechnology company Regeneron Pharmaceuticals, Inc. (REGN) reported on Thursday that net income for the second quarter increased to $1.43 billion or $12.41 per share from $968 million or $8.50 per share in the prior-year quarter.

Excluding items, adjusted earnings for the quarter $1.35 billion or $11.56 per share, compared to $1.18 billion or $10.24 per share in the year-ago quarter.

On average, 23 analysts polled by Thomson Reuters expected the company to report earnings of $10.61 per share for the quarter. Analysts' estimates typically exclude special items.

Total revenue for the quarter grew 12 percent to $3.55 billion from $3.16 billion in the same quarter last year. Analysts were looking for revenues of $3.38 billion for the quarter.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

read more
Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU

Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU

Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization of odronextamab to treat adults with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.
RTTNews | hace 423
Regeneron Pharma Q4 Results Top Estimates - Update

Regeneron Pharma Q4 Results Top Estimates - Update

Regeneron Pharmaceuticals, Inc. (REGN) reported on Friday that net income for the fourth quarter declined 3 percent to $1.16 billion or $10.19 per share from $1.20 billion or $10.50 per share in the prior-year quarter.
RTTNews | hace 570
Regeneron Completes Acquiring Sanofi's Stake In Libtayo

Regeneron Completes Acquiring Sanofi's Stake In Libtayo

Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that it has completed the acquisition of French drug major Sanofi's (SNYNF, SNY) stake in Libtayo (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization, and manufacturing rights to the medicine originally discovered in Regeneron's laboratories. The intent to purchase Libtayo was announced on June 2, 2022.
RTTNews | hace 1151
Bay Street May Open On Weak Note

Bay Street May Open On Weak Note

Canadian shares may open on a weak note Monday morning, tracking lower metal prices and European stocks. However, energy stocks may find support on higher oil prices, and help limit market's downside.
RTTNews | hace 1h 4min
Dollar Extends Losses Amidst Powell's Dovish Surprise

Dollar Extends Losses Amidst Powell's Dovish Surprise

A markedly dovish tone in Fed Chair Jerome Powell's speech at the Jackson Hole symposium on Friday weakened the Dollar, resulting in further losses for the currency during the week ended August 22.
RTTNews | hace 1h 49min
German Ifo Business Confidence Strongest Since 2024

German Ifo Business Confidence Strongest Since 2024

German business sentiment hit the highest level in more than two years in August on expectations that the fiscal stimulus would help to kickstart the economic recovery. The business climate index rose to 89.0 in August from 88.6 in the previous month. This was the highest score since April 2024 and also came in above economists' forecast of 88.6. The German economy's recovery remains weak.
RTTNews | hace 1h 52min
CAC 40 Down Nearly 0.6% In Cautious Trade

CAC 40 Down Nearly 0.6% In Cautious Trade

French stocks remain in negative territory on Monday, with investors mostly making cautious moves, looking for some more clarity on U.S. - EU trade deal, and awaiting crucial inflation data from the region.
RTTNews | hace 2h 26min